Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with cystic fibrosis who would be eligible for treatment with the drug Orkambi if it were available on the NHS.

The number of patients aged 12 and over with cystic fibrosis homozygous for the F508del mutation, in the National Institute for Health and Care Excellence’s (NICE) guidance, that might be eligible for treatment with Orkambi (lumacaftor-ivacaftor) under its marketing authorisation was estimated to be approximately 4,000 during the topic selection considerations that led to the referral of Orkambi to NICE.